LAWRENCE, Mass., March 2, 2017 /PRNewswire/ -- NxStage
Medical, Inc. (NASDAQ: NXTM), a leading medical technology company
focused on advancing renal care, today announced that its next
generation hemodialysis system has received CE Mark approval.
This innovative system consists of new features and capabilities,
including a new touchscreen user interface and integrated blood
pressure monitor designed to enhance ease of use for patients
performing home hemodialysis.
"Our next generation system was developed with extensive patient
and customer feedback and builds on our decade long experience in
providing life-changing therapy with the NxStage® System One™ to
over 30 thousand patients in their homes around the world," said
Joseph E. Turk, president of NxStage
Medical, Inc. "We are very excited to expand our portfolio and
begin providing patients with new features and capabilities that
are designed to significantly improve their therapy
experience."
NxStage's next generation hemodialysis system is currently
under review for 510(k) clearance from the United States Food and
Drug Administration.
About the NxStage System One
The NxStage System One is the first and only truly portable
hemodialysis system cleared specifically by the FDA for home
hemodialysis and home nocturnal hemodialysis. Its simplicity and
revolutionary size (just over a foot tall) are intended to allow
convenient use in patients' homes and give patients the freedom to
travel with their therapy. When combined with the NxStage PureFlow™
SL Dialysis Preparation System, patients are able to further
simplify, using ordinary tap water to create dialysis fluid on-site
on-demand. Unlike conventional hemodialysis systems, the System One
requires no special infrastructure to operate. Under the guidance
of their physician, patients can use the NxStage System One, with
their trained partners, where, how and when it best meets their
needs, including while they are sleeping - at home or on vacation
and at a medically appropriate treatment frequency. In addition,
NxStage's Nx2me Connected Health® platform collects important
NxStage System One and patient information for flexible viewing,
monitoring and reporting that may improve patient management and
patient retention, as well as simplify alternative site care. The
System One is also used to provide a range of flexible therapy
options in more traditional care settings such as hospitals and
dialysis centers. Its safety and performance have been demonstrated
by experience with more than 14 million treatments with tens of
thousands of patients around the world.
http://www.nxstage.com/.
About NxStage Medical
NxStage Medical, Inc.
(Nasdaq: NXTM) is a leading medical technology company,
headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
end-stage renal disease (ESRD) and acute kidney failure. NxStage
also has established a small number of dialysis clinics committed
to the development of innovative care delivery models for patients
with ESRD. For more information on NxStage and its products and
services, please visit the Company's websites at www.nxstage.com
and www.nxstagekidneycare.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this release that are not clearly
historical in nature are forward-looking, and the words
"anticipate," "believe," "expect," "estimate," "plan," and similar
expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors including those that are discussed in
NxStage's filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K for the year ended
December 31, 2016. NxStage is under
no obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Contact:
Kristen K. Sheppard,
Esq.
VP, Investor Relations
ksheppard@nxstage.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nxstage-medical-announces-ce-mark-for-its-nxgen-hemodialysis-system-300417166.html
SOURCE NxStage Medical, Inc.